Atlantic Investment Management Likes This Chemicals Company

Atlantic Investment Management, a fund run by Alexander Roepers with about $2 billion in assets under management, has filed with the SEC to disclose that it has purchased 3.9 million shares of Rockwood Holdings, Inc. (NYSE:ROC). Rockwood is a $4 billion market cap company which developed specialty chemicals that are then used for a variety of functions, including auto bodies and pharmaceutical-related uses. Atlantic had initiated a position in the company in the fourth quarter of 2011, opening 2012 with 600,000 shares in its portfolio. The fund then approximately doubled its position in each of the last two quarters and reported owning 3 million shares at the end of June (find out what other stocks it owned in its portfolio). Atlantic’s most recent purchases give it 5.1% of Rockwood’s shares outstanding, triggering the requirement to file a 13D. So far this year the stock is up 27%, outperforming the market, though thanks to a rough period towards the end of last year it is only up 5% compared to a year ago.

Alexander Roepers

Atlantic now owns about the same number of shares- 3.9 million- that Iridian Asset Management owned at the end of the second quarter. Iridian is managed by special situations investors David Cohen and Harold Levy (see more stocks that Iridian likes). Event-driven investor Barry Rosenstein’s JANA Partners initiated a position of 1.1 million shares in Rockwood during the second quarter of 2012 (research more stock picks from JANA Partners).

According to Rockwood’s 10-Q, the business is down compared to 2011; revenue in the second quarter of 2012 was down 9% from the figures in the second quarter of last year. Operating income fell 7%. A large income tax benefit pulled net income higher than a year ago, but this only serves to mask the company’s struggles. Revenue in the first quarter of the year was about the same as in the first quarter of 2011, and over the first half of the year operating income was about flat. Just over half the company’s business in 2011 came from Europe, so the financials reflect negative impacts both from poor European macro and from the rise of the dollar compared to the euro.

As a basic materials company with significant exposure to Europe, Rockwood Holdings, Inc. carries a high beta of 2.5 and so would not make for a good investment for an investor who is bearish on global macro. The company has started paying a dividend, with a yield of 2.9%, but this amount of money could easily be lost in an investment in the company due to a bad day in the market. The stock trades at 9 times trailing earnings and 11 times forward earnings estimates, and so along with the yield there is some case to be made for it as a value play. However, investors would have to have some confidence (as Atlantic apparently does) that the company will be able to get through the next few quarters with its current revenue and earnings numbers intact.

PolyOne Corporation (NYSE:POL) is the closest peer for Rockwood Holdings, Inc. PolyOne carries a trailing P/E of 20, but sell-side expectations are for strong earnings per share growth next year and so the forward P/E is 13 (still above Rockwood’s despite the smaller market cap of $1.5 billion). Between the two we think that Rockwood is the better buy. Other specialty chemicals companies include RPM International Inc. (NYSE:RPM), Cytec Industries Inc (NYSE:CYT), and Huntsman Corporation (NYSE:HUN). RPM and Cytec look very similar from a valuation perspective- they both trade at 18 times trailing earnings and 14 times forward estimates- while Huntsman is considerably cheaper at a trailing P/E of only 11. All three of these companies grew their earnings last quarter compared to the same period in 2011. We would want to take a closer look at Huntsman but Rockwood looks cheaper than the rest of its peers.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!